The results from multiple investigations using different induction approaches suggest that better regimens are available and should be investigated further in the context of acute myeloid leukemia (AML) heterogeneity and emerging prognostic knowledge concerning cytogenetic and molecular abnormalities. Today, based on existing data, evaluating bone marrow on Days 10 to 14 for residual AML and reacting to the bone marrow findings may be a common practice, but is not validated by objective data.
No takes yet. Share an insight, caveat, or question.
Kantarjian et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: